Karyopharm Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Karyopharm Therapeutics

17/02/2025 13:34

* Karyopharm Therapeutics Inc  KPTI.OQ   KPTI.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 19 for the period ending December 31 2024
    * The Newton Massachusetts-based  company is expected to
report a
3.3% increase in revenue to $34.865 million from $33.75 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.The company's guidance on January 13 2025,
for the period ended December 31, was for revenue of $30.000
million.
    * ​LSEG's mean analyst estimate for Karyopharm Therapeutics
Inc is
for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karyopharm
Therapeutics Inc is $5.00​, above​ its last closing price
of $0.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.25       -0.26      -0.26     Met     1.1
 Jun. 30 2024  -0.29       -0.30      0.15      Beat    150.2
 Mar. 31 2024  -0.33       -0.33      -0.32     Beat    4.2​
 Dec. 31 2023  -0.31       -0.31      -0.36     Missed  -16.2
 ​​Sep.        -0.28       -0.28      -0.30     Missed  -7.1
 30 2023                                                
 Jun. 30 2023  -0.35       -0.34      -0.29     Beat    15.3​
 Mar. 31 2023  -0.36       -0.37      -0.30     Beat    18.5
 Dec. 31 2022  -0.35       -0.35      -0.43     Missed  -21.8
 This summary was machine generated February 17 at 13:34 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)